Myelofibrosis - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 10 PAGES: 125

More Info
									Myelofibrosis – Pipeline Review, H2 2011




                       Myelofibrosis - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1471IDB

                                                                                          Publication Date: October 2011




Myelofibrosis – Pipeline Review, H2 2011                                                                         GMDHC1471IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Myelofibrosis – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 8
      List of Figures .................................................................................................................................................................................................... 9
Introduction .............................................................................................................................................................................................................10
      Global Markets Direct Report Coverage ............................................................................................................................................................10
Myelofibrosis Overview ............................................................................................................................................................................................11
Therapeutics Development ......................................................................................................................................................................................12
      An Overview of Pipeline Products for Myelofibrosis ...........................................................................................................................................12
Myelofibrosis Therapeutics under Development by Companies ...............................................................................................................................14
Myelofibrosis Therapeutics under Investigation by Universities/Institutes.................................................................................................................16
Late Stage Products ................................................................................................................................................................................................19
      Comparative Analysis .......................................................................................................................................................................................19
Mid Clinical Stage Products .....................................................................................................................................................................................20
      Comparative Analysis .......................................................................................................................................................................................20
Early Clinical Stage Products ..................................................................................................................................................................................21
      Comparative Analysis .......................................................................................................................................................................................21
Myelofibrosis Therapeutics - Products under Development by Companies ..............................................................................................................22
Myelofibrosis Therapeutics - Products under Investigation by Universities/Institutes................................................................................................24
Companies Involved in Myelofibrosis Therapeutics Development ............................................................................................................................27
      Bristol-Myers Squibb Company .........................................................................................................................................................................27
      Sanofi-Aventis ...................................................................................................................................................................................................27
      AstraZeneca PLC ..............................................................................................................................................................................................28
      Eli Lilly and Company........................................................................................................................................................................................28
      Gilead Sciences, Inc. ........................................................................................................................................................................................29
      Infinity Pharmaceuticals, Inc. .............................................................................................................................................................................29
      YM BioSciences Inc. .........................................................................................................................................................................................30
      Novartis AG.......................................................................................................................................................................................................30
      Cephalon, Inc. ...................................................................................................................................................................................................31
      Astex Therapeutics Limited ...............................................................................................................................................................................31
      Celgene Corporation .........................................................................................................................................................................................32
      Incyte Corporation .............................................................................................................................................................................................32
      Threshold Pharmaceuticals, Inc. .......................................................................................................................................................................33
      Italfarmaco S.p.A...............................................................................................................................................................................................33
      S*BIO Pte Ltd....................................................................................................................................................................................................34
      PharmaMar, S.A................................................................................................................................................................................................34
Myelofibrosis - Therapeutics Assessment ................................................................................................................................................................35
      Assessment by Monotherapy Products .............................................................................................................................................................35
      Assessment by Combination Products ..............................................................................................................................................................36
      Assessment by Route of Administration ............................................................................................................................................................37
      Assessment by Molecule Type ..........................................................................................................................................................................39
Drug Profiles ...........................................................................................................................................................................................................41
      Pacritinib - Drug Profile .....................................................................................................................................................................................41
            Product Description ....................................................................................................................................................................................41
            Mechanism of Action...................................................................................................................................................................................41
            R&D Progress .............................................................................................................................................................................................41
      AZD1480 - Drug Profile .....................................................................................................................................................................................43
            Product Description ....................................................................................................................................................................................43


Myelofibrosis – Pipeline Review, H2 2011                                                                                                                      GMDHC1471IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                               Page(2)
Myelofibrosis – Pipeline Review, H2 2011


          Mechanism of Action...................................................................................................................................................................................43
          R&D Progress .............................................................................................................................................................................................43
     IPI-926 - Drug Profile ........................................................................................................................................................................................44
          Product Description ....................................................................................................................................................................................44
          Mechanism of Action...................................................................................................................................................................................44
          R&D Progress .............................................................................................................................................................................................44
     LBH589 - Drug Profile .......................................................................................................................................................................................45
          Product Description ....................................................................................................................................................................................45
          Mechanism of Action...................................................................................................................................................................................45
          R&D Progress .............................................................................................................................................................................................45
     AT9283 - Drug Profile .......................................................................................................................................................................................47
          Product Description ....................................................................................................................................................................................47
          Mechanism of Action...................................................................................................................................................................................47
          R&D Progress .............................................................................................................................................................................................47
     SB939 - Drug Profile .........................................................................................................................................................................................48
          Product Description ....................................................................................................................................................................................48
          Mechanism of Action...................................................................................................................................................................................48
          R&D Progress .............................................................................................................................................................................................48
     CYT387 - Drug Profile .......................................................................................................................................................................................49
          Product Description ....................................................................................................................................................................................49
          Mechanism of Action...................................................................................................................................................................................49
          R&D Progress .............................................................................................................................................................................................49
     INCB18424 - Drug Profile..................................................................................................................................................................................51
          Product Description ....................................................................................................................................................................................51
          Mechanism of Action...................................................................................................................................................................................51
          R&D Progress .............................................................................................................................................................................................51
     TH-302 - Drug Profile ........................................................................................................................................................................................53
          Product Description ....................................................................................................................................................................................53
          Mechanism of Action...................................................................................................................................................................................53
          R&D Progress .............................................................................................................................................................................................53
     CEP-41601 - Drug Profile..................................................................................................................................................................................55
          Product Description ....................................................................................................................................................................................55
          Mechanism of Action...................................................................................................................................................................................55
          R&D Progress .............................................................................................................................................................................................55
     SAR302503 - Drug Profile .................................................................................................................................................................................56
          Product Description ....................................................................................................................................................................................56
          Mechanism of Action...................................................................................................................................................................................56
          R&D Progress .............................................................................................................................................................................................56
     Aplidin - Drug Profile .........................................................................................................................................................................................57
          Product Description ....................................................................................................................................................................................57
          Mechanism of Action...................................................................................................................................................................................57
          R&D Progress .............................................................................................................................................................................................57
     Arsenic Trioxide + Ascorbic Acid - Drug Profile .................................................................................................................................................58
          Product Description ....................................................................................................................................................................................58
          Mechanism of Action...................................................................................................................................................................................58
          R&D Progress .............................................................................................................................................................................................58
     BMS-354825 - Drug Profile ...............................................................................................................................................................................59
          Product Description ....................................................................................................................................................................................59




Myelofibrosis – Pipeline Review, H2 2011                                                                                                                  GMDHC1471IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                          Page(3)
Myelofibrosis – Pipeline Review, H2 2011


          Mechanism of Action...................................................................................................................................................................................59
          R&D Progress .............................................................................................................................................................................................59
     Clofarabine + Melphalan + Alemtuzumab + Stem Cell Transplantation - Drug Profile ........................................................................................61
          Product Description ....................................................................................................................................................................................61
          Mechanism of Action...................................................................................................................................................................................61
          R&D Progress .............................................................................................................................................................................................61
     Campath - Drug Profile......................................................................................................................................................................................62
          Product Description ....................................................................................................................................................................................62
          Mechanism of Action...................................................................................................................................................................................62
          R&D Progress .............................................................................................................................................................................................62
     Vidaza - Drug Profile .........................................................................................................................................................................................63
          Product Description ....................................................................................................................................................................................63
          Mechanism of Action...................................................................................................................................................................................63
          R&D Progress .............................................................................................................................................................................................63
     Peripheral Blood Lymphocyte Therapy + Cyclophosphamide + Tacrolimus + Allogeneic Hematopoietic Stem Cell Transplantation + Peripheral
     Blood Stem Cell Transplantation + Total Body Irradiation - Drug Profile ............................................................................................................64
          Product Description ....................................................................................................................................................................................64
          Mechanism of Action...................................................................................................................................................................................64
          R&D Progress .............................................................................................................................................................................................64
     R115777 - Drug Profile......................................................................................................................................................................................66
          Product Description ....................................................................................................................................................................................66
          Mechanism of Action...................................................................................................................................................................................66
          R&D Progress .............................................................................................................................................................................................66
     Actimid - Drug Profile ........................................................................................................................................................................................67
          Product Description ....................................................................................................................................................................................67
          Mechanism of Action...................................................................................................................................................................................67
          R&D Progress .............................................................................................................................................................................................67
     Busulfan + Melphalan + Campath + Peripheral Blood Stem Cell Transplantation - Drug Profile ........................................................................68
          Product Description ....................................................................................................................................................................................68
          Mechanism of Action...................................................................................................................................................................................68
          R&D Progress .............................................................................................................................................................................................68
     Filgrastim + Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Mycophenolate Mofetil + Umbilical Cord Blood Transplantation +
     Radiation Therapy - Drug Profile .......................................................................................................................................................................69
          Product Description ....................................................................................................................................................................................69
          Mechanism of Action...................................................................................................................................................................................69
          R&D Progress .............................................................................................................................................................................................70
     Pomalidomide - Drug Profile..............................................................................................................................................................................71
          Product Description ....................................................................................................................................................................................71
          Mechanism of Action...................................................................................................................................................................................71
          R&D Progress .............................................................................................................................................................................................71
     Thalidomide - Drug Profile.................................................................................................................................................................................72
          Product Description ....................................................................................................................................................................................72
          Mechanism of Action...................................................................................................................................................................................72
          R&D Progress .............................................................................................................................................................................................72
     Myleran + Fludarabine + Thymoglobulin - Drug Profile ......................................................................................................................................73
          Product Description ....................................................................................................................................................................................73
          Mechanism of Action...................................................................................................................................................................................73
          R&D Progress .............................................................................................................................................................................................73
     Misulfan + Cytoxan + Folex + Prograf + Allogeneic Peripheral Blood Stem Cell Transplantation - Drug Profile .................................................74



Myelofibrosis – Pipeline Review, H2 2011                                                                                                                 GMDHC1471IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                         Page(4)
Myelofibrosis – Pipeline Review, H2 2011


          Product Description ....................................................................................................................................................................................74
          Mechanism of Action...................................................................................................................................................................................74
          R&D Progress .............................................................................................................................................................................................74
     Pegasys - Drug Profile ......................................................................................................................................................................................75
          Product Description ....................................................................................................................................................................................75
          Mechanism of Action...................................................................................................................................................................................75
          R&D Progress .............................................................................................................................................................................................75
     Zometa - Drug Profile ........................................................................................................................................................................................76
          Product Description ....................................................................................................................................................................................76
          Mechanism of Action............................................................................
								
To top